Funxional Therapeutics funxionaltherapeutics.com


Public lists: Pharma Startups (4732)

Funxional Therapeutics Ltd.'s focus is on broad-spectrum chemokine inhibitors. Its small molecule lead candidate has entered clinical development. The chemokine inhibitors will target a broad range of inflammatory conditions.

Funxional Therapeutics Ltd.'s focus is on broad-spectrum chemokine inhibitors. Its small molecule lead candidate has entered clinical development. The chemokine inhibitors will target a broad range of inflammatory conditions.

Company (Alive / Active)

Phone:

Fax:

4 Cross Street

CB1 2HW
United Kingdom

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
Funxional Therapeutics $12.5M May 7, 2010
See all 16 competitors

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related Funxional Therapeutics Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 4 investors

Competitors

Company Status Description Investors

CGI Pharmaceuticals

Branford, Connecticut, United States
AcquiredCGI Pharmaceuticals is a private, development-stage pharmaceutical company that has leveraged its small molecule chemistry and kinase biology expertise to discover and develop an innovative pipeline of small molecule therapeutics for multiple oncology and immunology-based indications.Login to see details

KAI Pharmaceuticals

South San Francisco, California, United States
AcquiredKAI Pharmaceuticals is a privately held, venture-backed drug discovery and development company with preclinical and clinical programs in acute cardiovascular and other diseases representing unmet medical needs. The company has applied its core expertise in the biology of PKC to develop highly potent and selective inhibitors and activators for each of the PKC isozymes for the treatment of a broad array of human diseases. KAI has received Fast-Track designation from the FDA for its lead compound, ...Show allLogin to see details
See all 16 competitors

Patents

Title Application Date Patent Date Status
(Patent / Application)